Renapta B.V. devel­ops sys­tems to improve the con­di­tion of patients with severe kid­ney impaire­ment.

The lead prod­uct of Renapta is a sys­tem for the selec­tive clear­ance of cer­tain ure­mic tox­ins from the blood of end stage renal dis­ease patients under­go­ing renal dial­y­sis.

Portfolio: MedSciences Seed Fund B.V.

Current prod­uct devel­op­ment stage: research.